

References QBRI Insights: Pink October - The Fight Against Breast Cancer

1. Sidransky D. Emerging molecular markers of cancer. *Nat Rev Cancer* (2002) 2(3):210-9. doi: 10.1038/nrc755. PubMed PMID: 11990857.
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* (2004) 10(8):789-99. doi: 10.1038/nm1087. PubMed PMID: 15286780.
3. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. *Nat Med* (2003) 9(1):123-8. doi: 10.1038/nm0103-123. PubMed PMID: 12514725.
4. Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. *Hum Pathol* (2011) 42(10):1499-504. doi: 10.1016/j.humphath.2010.04.023. PubMed PMID: 21676436.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* (2005) 353(16):1659-72. doi: 10.1056/NEJMoa052306. PubMed PMID: 16236737.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* (2005) 353(16):1673-84. doi: 10.1056/NEJMoa052122. PubMed PMID: 16236738.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* (2001) 344(11):783-92. doi: 10.1056/NEJM200103153441101. PubMed PMID: 11248153.
8. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* (2004) 5(3):207-13. doi: 10.1016/s1535-6108(04)00059-5. PubMed PMID: 15050912.
9. Waks AG, Winer EP. Breast Cancer Treatment: A Review. *JAMA* (2019) 321(3):288-300. doi: 10.1001/jama.2018.19323. PubMed PMID: 30667505.
10. Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med* (2019) 380(20):1929-40. doi: 10.1056/NEJMoa1813904. PubMed PMID: 31091374.
11. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* (2018) 379(8):753-63. doi: 10.1056/NEJMoa1802905. PubMed PMID: 30110579.
12. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* (2019) 20(6):806-15. doi: 10.1016/S1470-2045(19)30164-0. PubMed PMID: 31036468.



13. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* (2020) 21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. PubMed PMID: 31786121.
14. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, et al. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. *J Immunother Cancer* (2018) 6(1):34. doi: 10.1186/s40425-018-0347-5. PubMed PMID: 29747685; PubMed Central PMCID: PMC5944113.
15. Marconi R, Serafini A, Giovanetti A, Bartoleschi C, Pardini MC, Bossi G, et al. Cytokine Modulation in Breast Cancer Patients Undergoing Radiotherapy: A Revision of the Most Recent Studies. *Int J Mol Sci* (2019) 20(2). doi: 10.3390/ijms20020382. PubMed PMID: 30658426; PubMed Central PMCID: PMC6359111.
16. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast Cancer (Auckl)* (2015) 9(Suppl 2):17-34. doi: 10.4137/BCBCR.S29420. PubMed PMID: 26462242; PubMed Central PMCID: PMC4589089.